Get Started!
View the pharma page or request a consultation.
Pharma Resource Hub
Pharma Resource Hub
Pharma Resource Hub
A centralized repository featuring webinars with subject matter experts, pertinent and timely articles, GSV reports and related information.
Pharma Resource Hub
An interview with Mark Daniel, author of Growth Scale Value (GSV): Theory, Development, and Applications
In testing and in research, you must have an effective and reliable way to measure change. While raw scores have typically been the go-to for this important role, Growth Scale Values (GSVs) are quickly becoming the preferred method.
Are GSVs a more accurate measurement of change?
Growth Scale Values (GSVs) have a long 50-year history within research. However, GSVs are only now gaining traction as an alternative and more precise way to measure outcomes in clinical trials.
The Annual Gatlinburg Conference on Research and Theory in ID
Each year, Gatlinburg brings together numerous behavioral scientists from around the world to discuss their research and collaborations in related fields such as intellectual and developmental disabilities.
Taking an innovative approach to challenging COA translations
Over the last ten years, the Bayley Scales of Infant and Toddler Development, Third Edition (Bayley-3), a leading developmental assessment for children ages 1–42 months, has been referenced as an endpoint in 145 clinical trials (Citeline, 2024).
Clinical trial considerations: All scores are not created equal
Dr. Lynsey Psimas, Ph.D and Dr. Paul Williams PsyD attended CNS Summit 2023 and were fortunate to have the opportunity to present their poster, Precision Matters: An Analysis on How Various Scores Behave When Measuring Change Over Time; Factors That Inform Score Selection for the Best Results”.
Growth Scale Values Are Gaining Traction in Clinical Trials
Growth scale values (GSVs) have gained traction as a more precise option for measuring outcomes in clinical trials. Unlike raw scores and age equivalents, which lack precision to quantitatively measure developmental change, GSVs have distinct advantages for measuring change over time.
Testing cognition in clinical drug trials for Alzheimer’s Disease
Featuring Dr. John Harrison
The number of adults living with Alzheimer’s disease (AD) is expected to top 14 million by 2060. Not only is there no cure at this point, but current treatments haven’t been successful, and clinical trials to develop new therapeutic interventions keep failing. What’s holding back novel treatment option breakthroughs?
Finding the best metrics for pediatric neurogenetic trials
Featuring Dr. Shapiro, Dr. Eisengart, and Dr. Harmatz
Neurogenetic disorders that impact how the brain functions affect up to three percent of children, but available evaluation tools aren’t sensitive enough to detect change in their developmental skills. This poses a challenge for clinical trial sponsors who are trying to assess potential treatments. Gain more expert insight into the difficulties associated with therapy in these trial settings.
Learn more about Diversity in Clinical Research and COA Development
Featuring Lynsey Psimas, Ph.D., Melinda Johnson, and Pia Windelov
Watch the webinar with Lionbridge to explore the role of diversity in endpoint development and generalizable outcomes. Attendees will delve into why including diverse samples in Clinical Outcome Assessments (COAs) development is critical. You'll discover the importance of bias reduction in COA Development and review COA translation and adaptation methodology.